cas 474943-04-9|| where to buy N-[(E,2S,3R)-1-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide

Produktname:N-[(E,2S,3R)-1-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide

IUPAC Name:N-[(2S,3R,4E)-1-{[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxyoctadec-4-en-2-yl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanamide

: CAS：474943-04-9; Molekulare Formel：C42H69N5O16; Reinheit：95%+

: Katalognummer：CM719472; Molekulargewicht：900.03

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge

Anfrage: sales@chemenu.com

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 474943-04-9 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

Produkt-Details

: CAS-Nr.:474943-04-9; Molekulare Formel:C42H69N5O16; Schmelzpunkt:-; SMILES-Code:CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)NC(=O)CCCCCNC1=CC=C(C2=NON=C12)[N+]([O-])=O; Dichte:

: Katalognummer:CM719472; Molekulargewicht:900.03; Siedepunkt:; Mdl-Nr.:MFCD03428077; Lagerung:

Category Infos

: Benzofurazans; Benzofurazans are important pharmaceutical intermediates. Benzofurazans are known bioisosteres of the nitro group. Both oxadiazoles and nitro groups have strong electron-withdrawing properties, but when optimizing drug-like properties such as activity, selectivity, and stability, the absence of standard charges in the oxadiazole structure may be more beneficial to drug products. What's more, nitro groups have been identified as toxic groups, and it is routine to remove or replace them in the early stages of drug development.